Investigational Drug Information for Ecopipam
✉ Email this page to a colleague
What is the development status for investigational drug Ecopipam?
Ecopipam is an investigational drug.
There have been 17 clinical trials for Ecopipam.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Tourette Syndrome, Syndrome, and Stuttering. The leading clinical trial sponsors are Emalex Biosciences Inc., Psyadon Pharma, and Nuventra.
Summary for Ecopipam
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 302 |
WIPO Patent Applications | 219 |
Japanese Patent Applications | 162 |
Clinical Trial Progress | Phase 2 (2012-12-01) |
Vendors | 23 |
Recent Clinical Trials for Ecopipam
Title | Sponsor | Phase |
---|---|---|
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization | Clario | Phase 1 |
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization | PPD | Phase 1 |
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization | Emalex Biosciences Inc. | Phase 1 |
Clinical Trial Summary for Ecopipam
Top disease conditions for Ecopipam
Top clinical trial sponsors for Ecopipam
US Patents for Ecopipam
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |